Hostname: page-component-76fb5796d-vfjqv Total loading time: 0 Render date: 2024-04-29T19:16:07.636Z Has data issue: false hasContentIssue false
  • English
  • Français

Dementia in Movement Disorders

Published online by Cambridge University Press:  18 September 2015

H. Teräväinen ,
M. Hietanen ,
J. Stoessl  and
D.B. Calne
H. Teräväinen
Affiliation:
Division of Neurology, Department of Medicine, UBC Health Sciences Centre Hospital, University of British Columbia, Vancouver and the Department of Neurology, University of Helsinki, Finland
M. Hietanen
Affiliation:
Division of Neurology, Department of Medicine, UBC Health Sciences Centre Hospital, University of British Columbia, Vancouver and the Department of Neurology, University of Helsinki, Finland
J. Stoessl
Affiliation:
Division of Neurology, Department of Medicine, UBC Health Sciences Centre Hospital, University of British Columbia, Vancouver and the Department of Neurology, University of Helsinki, Finland
D.B. Calne*
Affiliation:
Division of Neurology, Department of Medicine, UBC Health Sciences Centre Hospital, University of British Columbia, Vancouver and the Department of Neurology, University of Helsinki, Finland
*
The University of British Columbia, Health Sciences Centre Hospital, 2211 Wesbrook Mall, Vancouver, B.C., Canada V6T 1W5
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Of all the movement disorders, Huntington's disease has been most consistently associated with dementia, while it is only over the last decade that intellectual and cognitive decline have been recognized as common features of Parkinson's disease. It is now known that the pathology in these two conditions reflects differential involvement of the striatum. The Huntington lesion is primarily in the caudate, while the Parkinson lesion preferentially affects the putamen. Both conditions have more diffuse pathology, and dementia may also occur in a wide range of other extrapyramidal diseases, such as progressive supranuclear palsy, the parkinsonism-dementia complex of Guam, and certain spinocerebellar degenerations. Clinicopathological correlations will be reviewed in these disorders of primarily subcortical pathology, and comparisons will be made with Alzheimer's disease, a disorder of predominantly cortical pathology.

Type
Imaging of Demented Subjects
Information
Canadian Journal of Neurological Sciences , Volume 13 , Issue S4 , November 1986 , pp. 546 - 558
Copyright
Copyright © Canadian Neurological Sciences Federation 1986

References

1.Alzheimer, A.Ubereine eigenartige Erkrankungen der Hirnrinde. Allg Z Psychiat 1907; 64: 146–148.Google Scholar
2.Terry, R, Katzman, R.Senile dementia of the Alzheimer type: Defining a disease. In: Katzman, R, Terry, RD (Eds.), Neurology of Aging. Vol 22. Philadelphia, Davis 1983; pp. 51–84.Google Scholar
3.Roth, M.Diagnosis of senile and related forms of dementia. Aging 1978; 7: 71–85.Google Scholar
4.Shefer, VF.Absolute number of neurons and thickness of the cerebral cortex during aging, senile and vascular dementia, and Pick’s and Alzheimer’s diseases. Neurosci Behav Physiol 1973; 6: 319–324.CrossRefGoogle ScholarPubMed
3.Wood, PL, Etienne, P, Lal, S, Nair, NPV, Finlayson, MH, Gauthier, S, Palo, J, Haltia, M, Paetau, A, Bird, ED.A post-mortem comparison of the cholinergic system in Alzheimer’s disease and Pick’s disease. J Neurol Sci 1983; 62: 211–217.CrossRefGoogle ScholarPubMed
6.Jervis, GA.Alzheimer’s disease. Psychiatr Q 1937; 11: 5–18.CrossRefGoogle Scholar
7.McMenemy, WH.Alzheimer’s disease. J Neurol Psychiatry 1940; 3: 211–240.Google Scholar
8.Corsellis, JAN.Ageing and the dementias. In: Blackwood, W, Corsellis, JAN (Eds.), Greenfield’s Neuropathology. Chicago: Year Book Medical Publishers 1976; pp. 796–848.Google Scholar
9.Tomlinson, BE.The pathology of dementia. In: Wells, CE (Ed.), Dementia. 2nd ed. Philadelphia: FA Davis, 1977; pp. 113–153.Google ScholarPubMed
10.Terry, RD, Peck, A, DeTeresa, R, Schechter, R, Horoupian, DS.Some morphometric aspects of the brain in senile dementia of the Alzheimer type. Ann Neurol 1981; 10: 184–192.CrossRefGoogle ScholarPubMed
11.Mountjoy, CQ, Roth, M, Evans, NJR, Evans, HM.Cortical neuronal counts in normal elderly controls and demented patients. Neurobiol Aging 1983; 4: 1–11.CrossRefGoogle ScholarPubMed
12.Terry, RD, Davies, P.Dementia of the Alzheimer type. Ann Rev Neurosc 1980; 3: 77–95.CrossRefGoogle ScholarPubMed
13.Foster, NL, Chase, TN, Fedio, P, Patranas, NJ, Brooks, RA, Di Chiro, G.Alzheimer’s disease: Focal cortical changes shown by positron emission tomography. Neurology (Cleveland) 1983; 33: 961–965.Google Scholar
14.Foster, NL, Chase, TN, Mansi, L, Brooks, R, Fedio, P, Patronas, NJ, Di Chiro, G.Cortical abnormalities in Alzheimer’s disease. Ann Neurol 1984; 16: 649–645.CrossRefGoogle ScholarPubMed
15.Friedland, RP, Budinger, TF, Ganz, E.Regional cerebral metabolic alterations in dementia of the Alzheimer type: positron emission tomography with 18F fluorodeoxyglucose. J. Comput Assist Tomogr 1983; 7: 590–598.CrossRefGoogle ScholarPubMed
16.McGeer, PL, Kamo, H, Harrop, R, et al. Positron emission imaging in patients with clinically diagnosed Alzheimer’s disease. Can Med Assoc J 1986; 134: 597–607.Google ScholarPubMed
17.Whitehouse, PJ, Price, DL, Clark, AW, Coyle, JT, DeLong, MR.Alzheimer’s disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 1981; 10: 122–126.CrossRefGoogle ScholarPubMed
18.Whitehouse, PJ, Price, DL, Struble, RG, Clark, AW, Coyle, JT, DeLong, MR.Alzheimer’s disease and senile dementia: loss of neurons in the basal fore brain. Science 1982; 215: 1237–1239.CrossRefGoogle Scholar
19.Price, DL, Whitehouse, PJ, Struble, RG.Basal forebrain cholinergic systems in Alzheimer’s disease and related dementias. Neurosci comm 1982; 1: 84–92.Google Scholar
20.Arendt, T, Bigl, V, Arendt, A, Tennstedt, A.Loss of neurons in the nucleus basalis of Meynert in Alzheimer’s disease, paralysis agitans and Korsakoffs disease. Acta Neuropathol 1983; 61: 101–108.CrossRefGoogle ScholarPubMed
21.Arendt, T, Bigl, V, Ennstedt, A, Arendt, A.Neuronal loss in different parts of the nucleus basalis is related to neuritic plaque formation in cortical target areas in Alzheimer’s disease. Neurosci 1985; 14: 1–14.CrossRefGoogle ScholarPubMed
22.Rogers, JD, Brogan, D, Mirra, SS.The nucleus basalis of Meynert in neurological disease: A quantitative morphological study. Ann Neurol 1985; 17: 163–170.CrossRefGoogle ScholarPubMed
23.Herzog, AG, Kemper, TL.Amygdaloid changes in aging and dementia. Arch Neurol 1980; 37: 625–629.CrossRefGoogle ScholarPubMed
24.Bondareff, W, Mountjoy, CQ, Roth, M.Selective loss of neurones of origin of adrenergic projection to cerebral cortex (nucleus locus ceruleus) in senile dementia. Lancet 1981; 1: 783–784.CrossRefGoogle ScholarPubMed
25.Tomlinson, BE, Irving, D, Blessed, G.Cell loss in the locus ceruleus in senile dementia of Alzheimer type. J Neurol Sci 1981; 49: 419–428.CrossRefGoogle ScholarPubMed
26.Mann, DMA, Lincoln, J, Yates, PO, Stamp, JE, Toper, S.Changes in the monoamine containing neurones of the human CNS in senile dementia. Brit J Psychiat 1980; 136: 533–541.CrossRefGoogle ScholarPubMed
27.Mann, DM, Yates, PO, Hawkes, J.The noradrenergic system in Alzheimer and multi-infarct dementias. J Neurol Neurosurg Psychiatry 1982; 45: 113–119.CrossRefGoogle ScholarPubMed
28.Saper, CB, German, DC, White, CL. IIINeuronal pathology in the nucleus basalis and associated cell groups in senile dementia of the Alzheimer’s type. Possible role in memory loss. Neurology 1985; 35: 1089–1095.CrossRefGoogle Scholar
29.Clark, AW, Parhad, IM, Folstein, SE, Whitehouse, PJ, Hedreen, JC, Price, DL, Chase, GA.The nucleus basalis in Huntington’s disease. Neurology (Cleveland) 1983; 33: 1262–1267.Google Scholar
30.Dubois, B, Ruberg, M, Javoy-Agid, F, Ploska, A, Agid, Y.A subcortico-cortical cholinergic system is affected in Parkinson’s disease. Brain Res 1983; 288: 213–218.Google ScholarPubMed
31.Nakano, I, Hirano, A.Parkinson’s disease: Neuron loss in the nucleus basalis without concomitant Alzheimer’s disease. Ann Neurol 1984; 15: 415–418.CrossRefGoogle ScholarPubMed
32.Uhl, GR, Hilt, DC, Hedreen, JC, Whitehouse, PJ, Price, DL.Pick’s disease (lobar sclerosis): depletion of neurons in the nucleus basalis of Meynert. Neurology (Cleveland) 1983; 33: 1470–1473.Google Scholar
33.Tagliavini, F, Pilleri, G.Basal nucleus of Meynert. A neuropathological study in Alzheimer’s disease, simple senile dementia, Pick’s disease and Huntington’s chorea. J Neurol Sci 1983; 62: 243–260.CrossRefGoogle ScholarPubMed
34.Ball, MJ, Fishman, M, Hachinski, V, Biume, W, Fox, A, Krai, VA, Kirschen, AJ, Fox, H, Merskey, H.A new definition of Alzheimer’s disease: a hippocampal dementia. Lancet 1985; 1: 14–16.CrossRefGoogle ScholarPubMed
35.Brun, A, Gustafsson, L.Limbic lobe involvement in presenile dementia. Arch Psychiat Nervenkr 1978; 226: 79–93.CrossRefGoogle ScholarPubMed
36.Coyle, JT, Price, DL, DeLong, MR.Alzheimer’s disease: A disorder of cortical cholinergic innervation. Science 1983; 219: 1184–1190.CrossRefGoogle ScholarPubMed
37.Wisniewski, HM, Narang, HK, Terry, RD.Neurofibrillary tangles of paired helical filaments. J Neurol Sci 1976; 27: 173–181.CrossRefGoogle ScholarPubMed
38.Blessed, G, Tomlinson, BE, Roth, M.The association between quantitative measurements of dementia and senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry 1968; 114: 797–811.CrossRefGoogle ScholarPubMed
39.Perry, EK, Tomlinson, BE, Blessed, G, Bergman, K, Gibson, PH, Perry, RH.Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J 1978; 2: 1457–1459.CrossRefGoogle ScholarPubMed
40.Wilcock, GK, Esiri, MM, Bowen, DM, Smith, CCT.Alzheimer’s disease: correlation of cortical choline acetyltransferase activity with the seventy of dementia and histological abnormalities. J Neurol Sci 1982; 57: 407–417.CrossRefGoogle Scholar
41.Terry, R, Katzman, R.Senile dementia of the Alzheimer type: Defining a disease. In: Katzman, R, Terry, RD (Eds.), Neurology of Aging. Vol 22. Philadelphia, Davis 1983; pp. 51–84.Google Scholar
42.Ulrich, J.Alzheimer changes in nondemented patients younger than sixty-five: possible early stages of Alzheimer’s disease and senile dementiaof Alzheimer type. Ann Neurol 1985; 17: 273–277.CrossRefGoogle ScholarPubMed
43.Wisniewski, KE, Wisniewski, HM, Wen, GY.Occurrence of neuropathological changes and dementia of Alzheimer’s disease in Down’s syndrome. Ann Neurol 1985; 17: 278–282.CrossRefGoogle ScholarPubMed
44.Alvord, EC.The pathology of Parkinsonism. Part 11. An interpretation with special reference to other changes in the aging brain. In: McDovell, FC, Markham, CH (Eds.) Recent Advances in Parkinson’s disease. Philadelphia: FA Davis, 1971 ; pp. 131–161.Google Scholar
45.Boiler, F, Mizutani, T, Roessmann, V, Gambetti, P.Parkinson disease, dementia, and Alzheimer disease: clinicopathological correlations. Ann Neurol 1980; 7: 329–335.CrossRefGoogle Scholar
46.Steele, JC, Richardson, JC, Olszewski, J.Progressive supranuclear palsy. Arch Neurol 1964; 10: 333–359.CrossRefGoogle ScholarPubMed
47.Chen, L.Neurofibrillary change on Guam. Arch Neurol 1981; 38: 16–18.CrossRefGoogle ScholarPubMed
48.Wisniewski, K, Jervis, GA, Moretz, RC, Wisniewski, HM.Alzheimer neurofibrillary tangles in diseases other than senile and presenile dementia. Ann Neurol 1979; 5: 288–294.CrossRefGoogle ScholarPubMed
49.Corsellis, JAN, Bruton, CJ, Freeman-Browne, D.The aftermath of boxing. Psychol Med 1973; 3: 270–303.CrossRefGoogle ScholarPubMed
50.Uhl, GR, McKinney, M, Hedreen, JC, White, CL III, Coyle, JT, Whitehouse, PJ, Price, DL.Dementia pugilistica: loss of basal forebrain cholinergic neurons and cortical cholinergic markers. Ann Neurol 1982; 12: 99.Google Scholar
51.Bowen, DM, Smith, CB, White, P.Davison, AN.Neurotrans mitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain 1976; 99: 459–496.CrossRefGoogle Scholar
52.Davies, P.Neurotransmitter-related enzymes in senile dementia of the Alzheimer type. Brain Res 1979; 171: 319–327.CrossRefGoogle ScholarPubMed
53.Richter, JA, Perry, EK, Tomlinson, BE.Acetycholine and choline levels in post-mortem human brain tissue: preliminary observations in Alzheimer’s disease. Life Sci 1980; 26: 1683–1689.CrossRefGoogle Scholar
54.Perry, EK, Tomlinson, BE, Blessed, G, Perry, RH, Cross, AJ, Crow, TJ.Neuropathological and biochemical observations on the noradrenergic system in Alzheimer’s disease. J Neurol Sci 1981; 51: 279–287.CrossRefGoogle ScholarPubMed
55.Rossor, MN.Dementia. Lancet 1982; 2: 1220–1204.Google ScholarPubMed
56.Gottfries, C-G, Adolfsson, R, Aquillonius, S-M, Carlsson, A, Eckernäs, S-A, Nordberg, A, Oreland, L, Svennerholm, L, Wiberg, A, Winblad, B.Biochemical changes in dementia disorders of Alzheimer type (AD/SDAT). Neurobiol Aging 1983; 4: 261–271.CrossRefGoogle ScholarPubMed
57.McGeer, PL, McGeer, EG, Suzuki, J, Dolman, CE, Nagai, T.Aging, Alzheimer’s disease, and the cholinergic system of the basal forebrain. Neurology (Cleveland) 1984; 34: 741–745.Google Scholar
58.DeKosky, ST, Scheff, SW, Markesbery, WR.Laminar organization of cholinergic circuits in human frontal cortex in Alzheimer’s disease and aging. Neurology 1985; 35: 1425–1431.CrossRefGoogle ScholarPubMed
59.Perry, E, Curtis, M, Dick, DJ, Candy, JM, Atack, JR, Bloxham, CA, Blessed, G, Fairbairn, A, Tomlinson, BE, Perry, RH.Cholinergic correlates of cognitive impairment in Parkinson’s disease: Comparisons with Alzheimer’s disease. J Neurol Neurosurg Psychiatry 1985; 48: 413–421.CrossRefGoogle ScholarPubMed
60.Davies, P, Verth, AH.Regional distribution of muscarinic acetylcholine receptor in normal and Alzheimer’s-ty pe dementia brains. Brain Res 1978; 138: 385–392.CrossRefGoogle Scholar
61.Bartus, RT, Dean, RL, Beer, B, Lippa, AS.The cholinergic hypothesis of geriatric memory dysfunction. Science 1982; 217: 408–417.CrossRefGoogle ScholarPubMed
62.Cross, AJ, Crow, TJ, Ferrier, IN, Johnson, JA, Markkagis, D.Striatal dopamine receptors in Alzheimer-type dementia. Neurosci Lett 1984; 52: 1–6.CrossRefGoogle ScholarPubMed
63.Adolfsson, R, Gottfries, CG, Roos, BE, Winblad, B.Changes in brain catecholamines in patients with dementia of Alzheimer’s type. Br J Psychiatry 1979; 135: 216–223.CrossRefGoogle Scholar
64.Rossor, MN, Emson, PC, Mountjoy, CQ, Roth, M, lversen, LL.Reduced amounts of immunoreactive somatostatin in the temporal cortex in senile dementia of Alzheimer type. Neurosci Lett 1980; 20: 373–377.CrossRefGoogle ScholarPubMed
65.Carlsson, A.Aging and brain neurotransmitters. In: Cook, T, Gershen, S (Eds.), Strategies for the Development of an Effective Treatment for Senile Dementia. New Canaan, Mark Powley 1981 ; pp. 93–104.Google Scholar
66.Winblad, B, Adolfsson, R, Carlsson, A, Gottfries, C-G.Biogenic amines in brains of patients with Alzheimer’s disease. In: Gorkin, S, Davis, KL, Growdon, JH, Usdin, E, Wurtman, RJ (Eds.) Alzheimer’s disease: a report of progress in research. Aging Vol 19. New York, Raven Press, 1982; pp. 25–33.Google Scholar
67.Gibson, CJ, Ball, MJ.Hippocampal monoamine deficits in Alzheimer’s disease. J Neurochem 1983; Suppl 41: S20B.Google Scholar
68.Bondareff, W, Mountjoy, CQ, Roth, M.Loss of neurons of origin of the adrenergic projection to cerebral cortex (nucleus locus ceruleus) in senile dementia. Neurology (NY) 1982; 32: 164–168.CrossRefGoogle ScholarPubMed
69.Carlsson, A, Adolfsson, R, Aquilonius, S-M, Gottfries, C-H, Oreland, L, et al. Biogenic amines in human brain in normal aging, senile dementia, and chronic alcoholism. In: Goldstein, Met al (Eds.). Ergot Compounds and Brain Function: Neuroendocrine and Neuropsychiatrie Aspects. New York, Raven, 1980; pp. 95–304.Google Scholar
70.Gottfries, CG, Gottfries, I, Roos, BE.The investigation of homovanillinic acid in human brain and its correlation to senile dementia. Br J Psychiatry 1969; 115: 563–574.CrossRefGoogle Scholar
71.Yates, CM, Allison, Y, Simpson, J, Maloney, AFJ, Gordon, A.Dopamine in Alzheimer’s disease and senile dementia. Lancet 1979; 2: 851–852.CrossRefGoogle ScholarPubMed
72.Bareggi, SR, Franceschi, M, Bonnini, L, Zecca, L, Smime, S.Decreased CSF concentration of homovanillic acid and y-aminobutyric acid in Alzheimer’s disease. Arch Neurol 1982; 39: 709–712.CrossRefGoogle Scholar
73.Soininen, H, Macdonald, E, Rekonen, M, Riekkinen, PJ.Homovanillic acid and 5-hydroxyindoleacetic acid levels in cerebrospinal fluid of patients with senile dementiaof Alzheimer type. Acta Neurol Scand 1981; 64: 101–107.CrossRefGoogle ScholarPubMed
74.Palmer, AM, Sims, NR, Bowen, DM, Neary, D, Palo, J, Wikstrom, J, Davison, AN.Monoamine metabolite concentrations in lumbal cerebrospinal fluid of patients with histologically verified Alzheimer’s dementia. J Neurol Neurosurg Psychiatry 1984; 47: 481–484.CrossRefGoogle Scholar
75.Cross, AJ, Crow, TJ, Perry, EK, Perry, RH, Blessed, G, Tomlinson, BE.Reduced dopamine-beta-hycroxylase activity in Alzheimer’s disease. Brit Med J 1981; 282: 93–94.CrossRefGoogle ScholarPubMed
76.Reisine, TD, Yamamura, HI, Bird, ED, Spokes, E, Enna, SJ.Preand postsynaptic neurochemical alterations in Alzheimer’s disease. Brain Res 1978; 159: 477–481.CrossRefGoogle Scholar
77.Cross, AJ, Crow, TJ, Ferrier, IN, Johnson, JA, Bloom, SR, Corsellis, JAN.Serotonin receptor changes in dementia of the Alzheimer type. J Neurochem 1984; 43: 1574–1581.CrossRefGoogle ScholarPubMed
78.Davies, P, Katzman, R, Terry, RD.Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer disease and Alzheimer senile dementia. Nature 1980; 288: 279–280.CrossRefGoogle Scholar
79.Beal, MF, Mazurek, MF, Chatta, G, Bird, ED, Martin, JB, Reduced numbers of somatostatin receptors in the cerebral cortex in Alzheimer’s disease. Science 1985; 229: 289–291.CrossRefGoogle ScholarPubMed
80.Roberts, GW, Crow, TJ, Polak, JM.Location of neuronal tangles in somatostatin neurones in Alzheimer’s disease. Nature 1985; 314: 92–94.CrossRefGoogle ScholarPubMed
81.Morrison, JH, Rogers, J, Scherr, S, Benoit, R, Bloom, FE.Somatostatin immunoreactivity in neuritic plaques of Alzheimer’s patients. Nature 1985; 314: 90–93.CrossRefGoogle ScholarPubMed
82.Rossor, MN, Emson, PC, lversen, LL, Mountjoy, CQ, Roth, M, Fahrenkrug, J, Rehfeld, JF.Neuropeptides and neurotransmitters in cerebral cortex in Alzheimer’s disease. In: Corkin, S, Davis, L, Growdon, JH, Usdin, E, Wurtman, RJ (Eds). Alzheimer’s disease: A report of progress, Ageing Vol 19, New York, Raven 1982; pp. 15–24.Google Scholar
83.Rossor, MN, Garrett, NJ, Johnson, AL, Mountjoy, CQ, Roth, M, lversen, LL.A post-mortem study of the cholinergic and GABA systems in senile dementia. Brain 1982; 105: 313–330.CrossRefGoogle ScholarPubMed
84.Yates, CM, Harmer, AJ, Rosie, R, et al. Thyrotropin-releasing hormone, luteinizing hormone-releasing hormone and substance P immunoreactivity in post-mortem brains from cases of Alzheimer type dementia and Down’s syndrome. Brain Res 1983; 258: 45–52.CrossRefGoogle ScholarPubMed
85.Davies, P, Terry, RD.Cortical somatostatin-like immunoreactivity in cases of Alzheimer’s disease and senile dementia of Alzheimer type. Neurobiol Ageing 1981; 2: 9–14.CrossRefGoogle Scholar
86.Perry, EK, Atack, JR, Perry, RH, Hardy, JA, Dodd, PR, Edwardson, JA, Blessed, G, Tomlinson, BE, Fairbarn, AF.Intralaminarneurochemical distributions in human midtemporal cortex: comparison between Alzheimer’s disease and normal. J Neurochem 1984; 42: 1402–1410.CrossRefGoogle ScholarPubMed
87.Francis, PT, Palmer, AM, Sims, NR, Bowen, DM, Davison, AN, Esiri, MM, Neary, D, Snowden, JS, Wilcock, GK.Neurochemical studies of early-onset Alzheimer’s disease. N Engl J Med 1985; 313: 7–11.CrossRefGoogle ScholarPubMed
88.Mayeux, R, Stern, Y, Spanton, S.Heterogeneity in dementia of the Alzheimer type: Evidence of subgroups. Neurology 1985; 35: 453–461.CrossRefGoogle ScholarPubMed
89.McKhann, G, Drachman, D, Folstein, M, Katzman, R, Price, D, Stadlan, EM.Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS- ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology 1984; 34: 939–944.CrossRefGoogle ScholarPubMed
90.Mölsä, PK, Marttila, RJ, Rinne, UK. Extrapyramidal signs in Alzheimer’s disease. Neurology (Cleveland) 1984, 34: 1114–1116.Google Scholar
91.Aikawa, H, Suzuki, K, Iwasaki, Y, Izuka, R.Atypical Alzheimer’s disease with spastic paresis and ataxia. Ann Neurol 1985; 17: 297–300.CrossRefGoogle ScholarPubMed
92.Huntington, G.On chorea. Med Surg Reporter 1872; 26: 317–321.Google Scholar
93.Denny-Brown, D.The basal ganglia. London: Oxford University Press 1962.Google Scholar
94.Bruyn, GW.Huntington’s chorea: historical, clinical and laboratory synopsis. In: Vinken, PJ, Bruyn, GW (Eds.), Handbook of Clinical Neurology. Vol 6. Amsterdam: North Holland, 1968; pp. 298–378.Google Scholar
95.Starr, A.A disorder of rapid eye movements in Huntington’s chorea. Brain 1967; 90: 545–564.CrossRefGoogle ScholarPubMed
96.McDowell, FH, Lee, EJ, Sweet, RD.Extrapyramidal disease. In: Baker, AB, Baker, LH (Eds.), Clinical neurology. New York: Harper 1978; pp. 1–67.Google Scholar
97.Sax, DS, Myers, RH, Wolf, PA, Bird, ED, Schoenfeld, M.Late onset Huntington disease. Neurology 1982; 32: A186.Google Scholar
98.Meyers, RM, Goldman, D, Bird, ED, Sax, DS, Merril, CR, Schoenfeld, M, Wolf, PA.Maternal transmission in Huntington’s disease. Lancet 1983; 1: 208–210.CrossRefGoogle Scholar
99.Bird, MT, Paulson, GW.The rigid form of Huntington’s chorea. Neurology 1971; 21: 271’276.CrossRefGoogle ScholarPubMed
100.Low, PA, Allsop, JL, Halmagyi, GM.Huntington’s chorea: the rigid form (Westphal variant) treated with levodopa. Med J Aust 1974; 1: 393–394.CrossRefGoogle ScholarPubMed
101.Oliver, J, Dewhurst, K.Childhood and adolescent forms of Huntington’s disease. J Neurol Neurosurg Psychiatry 1969; 32: 455–459.CrossRefGoogle ScholarPubMed
102.Byers, RK, Gilles, FH, Fung, C.Huntington’s disease in children. Neurology 1973; 23: 561–569.CrossRefGoogle ScholarPubMed
103.Mayeux, R, Stern, Y.Emotional changes associated with basal ganglia disorders. In: Heilman, K, Satz, P (Eds.), The Neuropsychology of Human Emotion. New York: Guilford Press, 1983.Google Scholar
104.Reed, TE, Chandler, JH, Hughes, EM, Davidson, RT.Huntington’s chorea in Michigan. 1. Demography and genetics. Am J Hum Genet 1958; 10: 201–225.Google Scholar
105.Folstein, SE, Folstein, MF, McHugh, PR.Psychiatric syndromes in Huntington’s disease. Adv Neurol 1979; 23: 281–289.Google Scholar
106.Lieberman, A, Dziatolowski, M, Kupersmith, M, Serby, M, Goodgold, A, Korein, J, Goldstein, M.Dementia in Parkinson disease. Ann Neurol 1979; 6: 355–359.CrossRefGoogle ScholarPubMed
107.Lieberman, A, Dziatolowski, M, Neophytides, A, et al. Dementias of Huntington’s and Parkinson’s disease. Adv Neurol 1979; 23: 273–280.Google Scholar
108.Caine, ED, Shoulson, I.Psychiatric syndromes in Huntington’s disease. Am J Psychiatry 1983; 140: 728–733.Google ScholarPubMed
109.Brothers, C.Huntington’s chorea in Victoria and Tasmania. J Neurol Sci 1964; 1: 405–420.CrossRefGoogle ScholarPubMed
110.Lyle, OE, Gottesman, II. Subtle cognitive deficits as 15-to-20 year precursors of Huntington’s disease. In: Chase, TN, Wexler, NS, Barbeau, A (Eds.), Advances in Neurology, vol 23, New York: Raven Press, 1979; pp. 227–238.Google Scholar
111.Dewhurst, K, Oliver, JE, McKnight, AL.Socio-psychiatric consequences of Huntington’s disease. Br J Psychiatry 1970; 116: 255–258.CrossRefGoogle ScholarPubMed
112.Trimble, M. (Ed) Neuropsychiatry. New York: John Wiley and Sons, 1981.Google Scholar
113.Fedio, P, Cox, CS.Neophytides, A, Ghislane, CF, Chase, TN.Neuropsychological profile of Huntington’s disease: Patients and those at risk. In: Chase, TN, Wexler, NS, Barbeau, A (Eds.), Advances in Neurology, vol 23, New York: Raven Press, 1979; pp. 239–255.Google Scholar
114.Weingartner, H, Caine, ED, Ebert, MH.Encoding processes. Learning and recall in Huntington’s disease. In: Chase, TN, Wexler, NS, Barbeau, A (Eds.). Advances in Neurology, vol 23, New York: Raven Press 1979; pp. 215–226.Google Scholar
115.Albert, MS, Butters, N, Brandt, J.Patterns of remote memory in amnesic and demented patients. Arch Neurol 1981; 38: 495–500.CrossRefGoogle ScholarPubMed
116.Fisher, JM, Kennedy, JL, Caine, ED, Shoulson, I.Dementia in Huntington disease: A cross-sectional analysis of intellectual decline. In: Mayeux, R, Rosen, WG (Eds.), New York, Raven Press 1983; pp. 229–238.Google ScholarPubMed
117.Rosen, WG.Clinical and neuropsychological assessment of Alzheimer disease. In: Mayeux, R, Rosen, WG (Eds.), The Dementias. New York, Raven Press, 1983; pp. 51–64.Google Scholar
118.Sax, DS, O’Donnell, L, Butters, N, Menzer, L, Montgomery, K, Kayne, HL.Computed tomographic, neurologic, and neuropsychological correlates of Huntington’s disease. Intern J Neurosci 1983; 18: 21–36.CrossRefGoogle ScholarPubMed
119.Fuld, PA.Test profile of cholinergic dysfunction and of Alzheimer-type dementia. J Clin Neuropsych 1984; 6: 380–392.CrossRefGoogle ScholarPubMed
120.Aminoff, MJ, Marshall, J, Smith, EM, Wyke, MA.Pattern of intellectual impairment in Huntington’s chorea. Psychol Med 1975: 5: 169–172.CrossRefGoogle ScholarPubMed
121.Haymaker, W, Mehler, WF, Schiller, F.Extrapyramidal motor disorders. In: Haymaker, W (Ed.), Bing’s local diagnosis in neurological diseases. 15th ed. St. Louis: CV Mosby 1969; pp. 404–440.Google Scholar
122.Terrence, CF, Delaney, JF, Alberts, MC.Computed tomography for Huntington’s disease. Neuroradiology 1977; 13: 173–175.CrossRefGoogle ScholarPubMed
123.Neophytides, AN, DiChiro, G, Barron, SA, Chase, TN.Computed axial tomography in Huntington’s disease and persons at risk for Huntington’s disease. Adv Neurol 1979; 23: 185–191.Google Scholar
124.Dreese, MJ, Netsky, MG.Degenerative disorders of the basal ganglia. In: Minckler, J (Ed.), Pathology of the nervous system. New York: McGraw-Hill 1968; pp. 1185–1204.Google Scholar
125.Lange, H, Thörner, G, Hopf, A, Shröder, KF.Morphometric studies of the neuropathological changes in choreatic diseases. J Neurol Sci 1976; 28: 401–425.CrossRefGoogle ScholarPubMed
126.Dom, R, Malfroid, M, Baro, F.Neuropathology of Huntington’s chorea. Studies of the ventrobasal complex of the thalamus. Neurology 1976; 26: 64–68.CrossRefGoogle ScholarPubMed
127.Bruyn, GW, Bots, GTAM, Dom, R.Huntington’s chorea: current neuropathological status. In: Chase, TN, Wexler, NS, Barbeau, A (Eds.), Advances in neurology, vol 23, New York: Raven Press, 1979; pp. 83–94.Google Scholar
128.Roos, RAC, Pruyt, JFM, de Vries, J, Both, GTAM.Neuronal distribution in the putamen in Huntington’s disease. J Neurol Neurosurg Psychiatry 1985; 48: 422–425.CrossRefGoogle ScholarPubMed
129.Bugiani, O, Tabaton, M, Cammarata, S.Huntington, ’s disease: survival of large striatal neurones in the rigid variant. Ann Neurol 1984; 15: 154–156.CrossRefGoogle Scholar
130.McCaughley, WTE.The pathologic spectrum of Huntington’s chorea. J Nerv Ment Dis 1961; 133: 91–103.CrossRefGoogle Scholar
131.Bird, ED, Mackay, AVP, Rayner, CN, lversen, LL.Reduced glutamicacid-decarboxylase activity in post-mortem brain in Huntington’s chorea. Lancet 1973; 1: 1090–1092.CrossRefGoogle ScholarPubMed
132.McGeer, PL, McGeer, EG, Fibiger, HC.Cholineacetylase and glutamic acid decarboxylase in Huntington’s chorea. A preliminary study. Neurolog (Minneap.) 1973; 23: 912–917.Google Scholar
133.Perry, TL, Hansen, S, Kloster, M.Huntington’s chorea-deficiency of y-aminobutyric acid in brain. New Engl J Med 1973; 288: 337–342.CrossRefGoogle Scholar
134.Bird, ED, lversen, LL.Huntington’s chorea-postmortem measurement of glutamic acid decarboxylase, choline asetyl transferase and dopamine in basal ganglia. Brain 1974; 97: 457–472.CrossRefGoogle Scholar
135.Urquhart, N, Perry, TL, Hansen, S, Kennedy, J.GABA content and glutamic acid decarboxylase activity in brain of Huntington’s chorea patient and control subjects. J Neurochem 1975; 24: 1071–1075.CrossRefGoogle ScholarPubMed
136.Bird, ED.Biochemical studies on y-aminobutyric acid metabolism in Huntington’s chorea. In: Bradford, HF, Marsden, CD (Ed.), Biochemistry and Neurology. New York: Academic Press. 1976; pp. 83–92.Google Scholar
137.Sourkes, TL.Parkinson’s disease and other disorders of the basal ganglia. In: Siegel, GJ, Alberts, RW, Katzman, R, Agranoff, BW (Eds.), Basic Neurochemistry. 2nd ed. Boston: Little, Brown, 1976; pp. 668–684.Google Scholar
138.Enna, SJ, Stern, LZ, Wastek, GJ, Yamamura, HI.Cerebrospinal fluid y-aminobutyric acid variations in neurological diseases. N Engl J Med 1977; 34: 683–685.Google Scholar
139.Bala Manyam, NV, Hare, TA, Katz, L, Glaeser, BS.Huntington’s disease. Cerebrospinal fluid GABA levels in at-risk individuals. Arch Neurol 1978; 35: 728–730.Google Scholar
140.Perry, TL, Wright, JM, Hansen, S, Thomas, SMB, Allan, BM, Baird, PA, Diewold, MA.A double-blind clinical trial of izoniazid in Huntington disease. Neurology (Ny) 1982; 32: 354–358.CrossRefGoogle Scholar
141.Van Ness, PC, Watkins, AE, Bergman, MO, Tourtelotte, WW, Olsen, RW.y-aminobutyric acid receptors in normal human brain and Huntington disease. Neurology (Ny) 1982; 32: 63–68.CrossRefGoogle Scholar
142.Stahl, WL, Swanson, PD.Biochemical abnormalities in Huntington’s chorea brains. Neurology 1974; 24: 813–819.CrossRefGoogle ScholarPubMed
143.Wu, JY, Bird, ED, Chen, MS, Huang, WM.Studies of neurotransmitter enzymes in Huntington’s chorea. Adv Neurol 1979; 23: 527–536.Google Scholar
144.Spokes, EGS.Dopamine in Huntington’s disease; a study of postmortem brain tissue. Adv Neurol 1979; 23: 481–493.Google Scholar
145.Melamed, E, Hefti, F, Bird, ED.Huntington chorea is not associated with hyperactivity of nigrostriatal dopaminergic neurons: Studies in postmortem brain tissues and in rates with kainic acid lesions. Neurology (Ny) 1982; 32: 640–644.CrossRefGoogle ScholarPubMed
146.Kuhl, DE, Phelps, ME, Markham, CH, Metter, EJ, Riege, WH, Winter, J.Cerebral metabolism and atrophy in Huntington’s disease determined by 18FDG and computed tomographic scan. Ann Neurol 1982; 425–434.CrossRefGoogle ScholarPubMed
147.Hayden, MR, Martin, WRW, Stoessl, AJ, et al. Positron emission tomography in the early diagnosis of Huntington disease. Neurology 1986 (in press).CrossRefGoogle Scholar
148.Stoessl, AJ, et al. In preparation. Figure 2. 1986.Google Scholar
149.Metter, EJ, Riege, WH, Kameyama, M, Kuhl, DE, Phelps, ME.Cerebral metabolic relationships for selected brain regions in Alzheimer’s, Huntington’s and Parkinson’s diseases. JCBF Metab 1984; 4: 500–506.Google ScholarPubMed
150.Aronin, N, Cooper, PE, Lorenz, LJ, Bird, ED, Sagar, SM, Leeman, SE, Martin, JB.Somatostatin is increased in the basal ganglia in the Huntington’s disease. Ann Neurol 1983; 13: 519–526.CrossRefGoogle Scholar
151.Kanazawa, I, Bird, E, O’Connell, R, Powell, D.Evidence for a decrease in substance P content of substantia nigra in Huntington’s chorea. Brain Res 1977; 120: 387–392.CrossRefGoogle ScholarPubMed
152.Arrequi, A, Bennett, JP, Bird, ED, Yamamusa, HI, Iversen, LL, Snyder, SH.Huntington’s chorea: selective depletion of activity of angiotensin converting enzyme in the corpus striatum. Ann Neurol 1977; 2: 294–298.CrossRefGoogle Scholar
153.Emson, PC, Rossor, MN, Hunt, SP, et al. Distribution and postmortem stability of substance P, met-encephalin, vasoactive intestinal polypeptide and cholecystokinin in normal human brain and Huntington’s disease. In: Rose, FC (Ed.) Metabolic Disorders of the Nervous System. Pitman, Marshfield 1981; pp. 312–321.Google Scholar
154.Pittaway, KM, Reynolds, GP, Emson, PC.Decreased proline endopeptidase activity in basal ganglia in Huntington’s disease. J Neurochem 1984; 43: 878–880.CrossRefGoogle ScholarPubMed
155.Marshall, PE, Landis, DM.Huntington’s disease is accompanied by changes in the distribution of somatostatin-containing neuronal processes. Brain Res 1985; 329: 71–82.CrossRefGoogle ScholarPubMed
156.Martin, WE, Resch, JA, Baker, AB.Juvenile parkinsonism. Arch Neurol 1971; 25: 494–500.CrossRefGoogle ScholarPubMed
157.Spellman, GG.Report of familiar cases of parkinsonism. JAMA 1962; 179: 160–162.Google Scholar
158.Kuhl, DE, Metter, EJ, Riege, WH.Patterns of local cerebral glucose utilization determined in Parkinson’s disease by the (18F) fluorodeoxyglucose method. Ann Neurol 1984; 15: 419–424.CrossRefGoogle ScholarPubMed
159.Martin, WRW, Stoessl, AJ, Adam, MJ, Ammann, W, Bergstrom, M, Harrop, R, Laihinen, A, Rogers, JG, Ruth, TJ, Sayre, C, Pate, BD, Caine, DB.Positron emission tomography in Parkinson’sdisease: glucose and dopa metabolism. Adv Neurol 1986 (in press).CrossRefGoogle Scholar
160.Pollock, M, Hornabrook, RW.The prevalence, natural history and dementia of Parkinson’s disease. Brain 1966; 89: 429–448.CrossRefGoogle ScholarPubMed
161.Mindham, RHS.Psychiatric symptoms in parkinsonism. J Neurol Neurosurg Psychiatry 1970; 213: 456–466.Google Scholar
162.Martin, WE, Loewenson, RB, Resch, JA, Baker, AB.Parkinson’s disease. Clinical analysis of 100 patients. Neurology 1973; 23: 783–790.Google ScholarPubMed
163.Mamila, RJ, Rinne, UK.Dementia in Parkinson’s disease. Acta Neurol Scand 1976; 54: 431–441.Google Scholar
164.Sweet, RD, McDowell, FH, Ferguson, JS, Loranger, AW, Goodell, H.Mental symptoms in Parkinson’s disease during chronic treatment with levodopa. Neurology 1976; 26: 305–310.CrossRefGoogle ScholarPubMed
165.Hakim, AM, Mathieson, G.Dementia in Parkinson disease: a neuropathological study. Neurology 1979: 29: 1209–1214.CrossRefGoogle Scholar
166.DeSmet, Y, Ruberg, M, Serdaru, M, Dubois, B, Lhermitte, F, Agid, Y.Confusion, dementia and anticholinergics in Parkinson’s disease. J Neurol Neurosurg Psychiatr 1982; 45: 1161–1164.CrossRefGoogle Scholar
167.Rajput, AH, Offord, K, Bard, MC, Kurland, LT.Epidemiological survey of dementia in parkinsonism and control population. In: Hassler, RG, Christ, JF (Eds.), Advances in Neurology, vol 40 1984; pp. 229–234.Google ScholarPubMed
168.Mjönes, H.Paralysis agitans, a clinical and genetic study. Acta Psychiatr Neur (Suppl) 1949; 54: 1–195.Google Scholar
169.Pirozzolo, FJ, Hansch, EC, Mortimer, JA, Webster, DD, Kuskowski, MA.Dementia in Parkinson disease. A neuropsychological analysis. Brain and Cognition 1982; 1: 71–83.Google ScholarPubMed
170.Mortimer, JA, Pirozzolo, FJ, Hansch, EC, Webster, DD.Relationship of motor symptoms to intellectual deficits in Parkinson’s disease. Neurology (Ny) 1982; 32: 133–137.CrossRefGoogle Scholar
171.Matthews, CG, Haaland, KY.The effect of symptom duration on cognitive and motor performance in parkinsonism. Neurology 1979; 29: 951–956.CrossRefGoogle ScholarPubMed
171a.Elizan, TS, Sroka, H, Maker, H, Smith, H, Yahr, MD.Dementia in idiopathic Parkinson’s Disease. Neuro Trans 1986; 65: 285–302.CrossRefGoogle ScholarPubMed
172.Brown, RG, Marsden, CD.How common is dementia in Parkinson’s disease. Lancet 1984; 2: 1262–1265.CrossRefGoogle ScholarPubMed
173.Lees, AJ.Parkinson’s disease and dementia. Lancet 1985; 1: 43–44.CrossRefGoogle ScholarPubMed
173a.Freedman, M, Oscar-Berman, M.Selective delayed response deficits in Parkinson’s and Alzheimer’s Disease. Arch Neurol. 1986 (in press).CrossRefGoogle ScholarPubMed
174.Mayeux, R, Stern, Y, Rosen, J, Leventhal, J.Depression, intellectual impairment, and Parkinson disease. Ann Neurol 1981; 31: 645–650.Google ScholarPubMed
175.Koller, WC.Disturbance of recent memory function in Parkinsonian patients on anticholinergic therapy. Cortex 1984; 20: 307–311.CrossRefGoogle ScholarPubMed
176.Hoehn, MM, Yahr, MD.Parkinsonism, onset, progression and mortality. Neurology (Minneapolis) 1967; 17: 427–442.CrossRefGoogle ScholarPubMed
177.Kogi, K.Significance of flicker test in industrial fatigue research with special reference to activating system of the brain. Rep Instit Sci Lab 1961; 58: 37–531.Google Scholar
178.Lees, AJ, Smith, E.Cognitive deficits in the early stages of Parkinson’s disease. Brain 1983; 106: 257–270.CrossRefGoogle ScholarPubMed
179.Levita, E, Riklan, M, Cooper, IS.Cognitive and perceptual performance, in parkinsonism as a function of age and neurological impairment. J Nerv Ment Dis 1964; 139: 516–520.CrossRefGoogle ScholarPubMed
180.Garron, DC, Klawans, HL, Narin, F.Intellectual functioning of persons with idiopathic parkinsonism. J Nerv Ment Dis 1972; 154: 445–451.CrossRefGoogle ScholarPubMed
181.Lieberman, AN.Parkinson’s disease: a clinical review. Am J Med Sci 1974; 267: 66–80.CrossRefGoogle ScholarPubMed
182.Loranger, AW, Goodell, H, McDowell, F, Lee, JE, Sweet, RD.Intellectual impairment in Parkinson’s syndrome. Brain 1972; 95: 405–412.CrossRefGoogle ScholarPubMed
183.Levita, E, Riklan, M.Integrative functions in parkinsonism. Perc Motor Skills 1970; 31: 379–385.CrossRefGoogle ScholarPubMed
184.Selby, G.Cerebral atrophy in Parkinsonism. J. Neurol Sci 1968; 6: 517–559.CrossRefGoogle ScholarPubMed
185.Alvord, EC.The pathology of Parkinsonism. Part II. An interpretation with special reference to other changes in the aging brain. In: McDowell, FC, Markham, CH (Eds.) Recent Advances in Parkinson’s disease. Philadelphia: FA Davis, 1971 ; pp. 131–161.Google Scholar
186.Sroka, H, Elizan, TS, Yahr, MD, Burger, A, Medazu, MR.Organic mental syndrome and confusional states in Parkinson’s disease. Arch Neurol 1981; 38: 339–342.CrossRefGoogle ScholarPubMed
187.Oppenheimer, DR.Diseases of the basal ganglia, cerebellum, and motor neurons. In: Blackwood, W, Corsellis, JAN (Eds.) Greenfield’s Neuropathology. Chicago: Year Book Medical Publishers, 1976; pp. 608–651.Google Scholar
188.Langston, JW, Forno, LS.The hypothalamus in Parkinson disease. Ann Neurol 1978; 3: 12–133.CrossRefGoogle ScholarPubMed
189.Javoy-Agid, F, Agid, Y.Is the mesocortical dopaminergic system involved in Parkinson disease? Neurology 1980; 30: 1326–1330.CrossRefGoogle ScholarPubMed
190.Hassler, R.Zur Pathologie der Paralysis agitans und des postence phalitischen Parkinsonismus. J Psychol u Neurol 1938; 8: 387–476.Google Scholar
191.Den Hartog Jager, WA, Betlehem, J.The distribution of Lewy bodies in the central and autonomic nervous system in idiopathic paralysis agitans. J Neurol Neurosurg Psychiat 1960; 23: 283–290.CrossRefGoogle ScholarPubMed
192.Alvord, EC, Forno, LS, Kusske, JA, Kauffman, RJ, Rhodes, JS, Goetowski, CR.The pathology of parkinsonism: a comparison of degenerations in cerebral cortex and brainstem. Adv Neurol 1975; 5: 175–193.Google Scholar
193.Mann, DMA, Yates, PO.Pathological basis for neurotransmitter changesin Parkinson’s disease. Neuropath Appl Neurobiol 1983; 9: 3–19.CrossRefGoogle Scholar
194.Ball, MJ.The morphological basis of dementia in Parkinson’s disease. Can J Neurol Sci 1984; 2: 180–184.CrossRefGoogle Scholar
195.Heston, LL, Mastri, AR, Anderson, VE, White, J.Dementia of the Alzheimer type: clinical genetics, natural history and associated conditions. Arch Gen Psychiatry 1981; 38: 1085–1090.CrossRefGoogle ScholarPubMed
196.Perry, RH, Tomlinson, BE, Candy, JM, Blessed, G, Foster, JF, Bloxham, CA, Perry, EK.Cortical cholinergic deficit in mentally impaired parkinsonian patients. Lancet 1983; 2: 789–790.CrossRefGoogle ScholarPubMed
197.Heilig, CW, Knopman, DS, Mastri, AR, Frey, W II. Dementia without Alzheimer pathology. Neurology 1985; 35: 762–765.CrossRefGoogle ScholarPubMed
198.Whitehouse, PJ, Hedreen, JC, White, CL, Price, DL.Basal forebrain neurons in the dementiaof Parkinson’s disease. Ann Neurol 1983; 13: 243–248.CrossRefGoogle Scholar
199.Candy, JM, Perry, RH, Perry, EK, Irving, D, Blessed, G, Fairbairn, AF, Tomlinson, BE.Pathological changes in the nucleus of Meynert in Alzheimer’s and Parkinson’s disease. J Neurol Sci 1983; 59: 277–289.CrossRefGoogle Scholar
200.Price, KS, Farley, IJ and Hornykiewicz, O.Neurochemistry of Parkinson’s disease: relation between striatal and limbic dopamine. Adv Biochem Pharmacol 1978; 19: 293–300.Google ScholarPubMed
201.Beart, PM.Transmitters and receptors in the basal ganglia. In: McKenzie, JS, Kemm, RE, Wilcock, LN (Eds.) The Basal Ganglia. New York, Plenum Press. 1984; pp. 261–296.CrossRefGoogle Scholar
202.Scatton, V, Javoy-Agid, F, Rouquir, L, Dubois, B, Agid, Y.Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson’s disease. Brain Res 1983; 275–328.Google ScholarPubMed
203.Hornykiewicz, O.Brain transmitter changes in Parkinson’s disease. In: Marsden, CD, Fahn, S (eds). Neurology 11. Movement Disorders. London: Butterworths 1982; pp. 41–58.Google Scholar
204.Hornykiewicz, O.Imbalance of brain monoamines and clinical disorders. Progr Brain Res 1982; 55: 419–429.CrossRefGoogle ScholarPubMed
205.Rinne, UK, Sonninen, V.Brain catecholamines and their metabolites in Parkinsonian patients. Arch Neurol 1973; 28: 107–110.CrossRefGoogle ScholarPubMed
206.Farley, IJ, Hornykiewicz, O.Noradrenaline in subcortical brain regions of patients with Parkinson’s disease and control subjects. In: Birkmayer, W, Hornykiewicz, O (Eds.), Advances in Parkinsonism. Basel: Editiones Roche, 1976; pp. 178–185.Google Scholar
207.Riederer, P, Birkmayer, W, Seeman, D, Wuketich, S.Brain noradrenaline and 3-methoxy-4-hydroxyphenylglycol in Parkinson’s syndrome. J Neur Transm 1977; 41: 241–246.CrossRefGoogle ScholarPubMed
208.Mayeux, R, Stern, Y, Cote, L, Williams, JBW.Altered serotonin metabolism in depressed patients with Parkinson’s disease. Neurology (Cleveland) 1984; 34: 642–646.CrossRefGoogle ScholarPubMed
209.Ruberg, M, Ploska, A, Javoy-Agid, F, Agid, Y.Muscarinic binding and choline acetyltransferase activity in parkinsonian subjects with reference to dementia. Brain Res 1982; 232: 129–139.CrossRefGoogle ScholarPubMed
210.Epelbaum, J, Ruberg, M, Moyse, ME, Javoy-Agid, F, Dubois, B, Agid, Y.Somatostatin and dementia in Parkinson’s disease. Brain Res 1983; 278: 376–379.CrossRefGoogle ScholarPubMed
211.Kuhl, DE, Metter, EJ, Benson, DF, Ashford, JW, Riege, WH, Fujikawa, DG, Markham, CH, Mazziotta, JC, Maltese, A, Dorsey, A.Similarities of cerebral glucose metabolism in Alzheimer’s and Parkinsonian dementia JCBF Metab. 1985; 5 (Supp. 1): S169–170.Google Scholar
212.Zetusky, WJ, Jankovic, J, Pirozzolo, JF.The heterogeneity of Parkinson’s disease. Neurology 1985; 35: 522–526.CrossRefGoogle ScholarPubMed
213.Bird, TB, Strahanan, BS, Sumi, SM, Raskind, M.Alzheimer’s disease: choline acetyltransferase activity in brain tissue from clinical and pathological subgroups. Ann Neurol 1983; 14: 284–293.CrossRefGoogle ScholarPubMed
214.Albert, ML, Feldman, RG, Willis, AL.The ‘subcortical dementia’ of progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 1974; 37: 121–130.CrossRefGoogle ScholarPubMed
215.Jackson, JA, Jankovic, J, Ford, J.Progressive supranuclear palsy: clinical features and response to treatment in 16 patients. Ann Neurol 1983; 13: 273–278.CrossRefGoogle ScholarPubMed
216.D’Antona, R, Baron, JC, Samson, Y, Serdaru, M, Viader, F, Agid, Y, Cambier, J.Subcortical dementia. Frontal cortex hypometabolism detected by positron tomography in patients with progressive supranuclear palsy. Brain 1985; 108: 785–799.Google ScholarPubMed
217.Tagliavini, F, Pilleri, G, Bouras, C, Constantinidis, J.The basal nucleus of Meynert in patients with progressive supranuclear palsy. Neurosci Lett 1984; 44: 37–42.CrossRefGoogle ScholarPubMed
218.Adams, RD, van Bogaert, L, van der Eecken, H.Striatonigral degeneration. J Neuropath Exp Neurol 1964; 23: 584–608.Google Scholar
219.Rebeiz, JJ, Kolodny, EH, Richardson, EP, Corticodentatonigral degeneration with neuronal achromasia. Arch Neurol 1968; 18: 20–33.CrossRefGoogle ScholarPubMed
220.Cummings, JL, Benson, DF (Eds.). Dementia: A Clinical Approach. Stoneham, Butterworth 1983.Google Scholar
221.Talland, GA.Cognitive function in Parkinson’s disease. J Nerv Ment Dis 1962; 135: 196–205.CrossRefGoogle ScholarPubMed
222.Asso, D.WAIS scores in a group of Parkinson patients. Br J Psychiatry 1969; 115: 555–556.CrossRefGoogle Scholar
223.Reitan, RM, Boll, TJ.Intellectual and cognitive functions in Parkinson’s disease. J Consult Clin Psychol 1971; 37: 364–369.CrossRefGoogle ScholarPubMed
224.Portin, R, Rinne, UK.Neuropsychological responses of parkinsonian patients to long-term levodopa treatment. In: Rinne, UK, Klinger, M, Stamm, G (Eds.) Parkinson’s disease. Current progress, problems and management. Amsterdam, Elsevier/North Holland Biomedical Press. 1980; pp. 271–304.Google Scholar
225.Villardita, C, Smirni, P, Le Pera, F, Zappala, G, Nicoletti, F.Mental deterioration, visuoperceptive disabilities and constructional apraxia in Parkinson’s disease. Acta Neurol Scand 1982; 66: 112–120.CrossRefGoogle ScholarPubMed
226.Direnfeld, LK, Albert, ML, Volicer, L, Langlais, PJ, Marquis, J, Kaplan, E.Parkinson’s disease. The possible relationship of laterality to dementia and neurochemical findings. Arch Neurol 1984; 41: 935–941.Google ScholarPubMed
227.Mayeux, R, Stern, Y.Intellectual dysfunction and dementia in Parkinson’s disease. In: Mayeux, R, Rosen, Y (Eds.) The Dementias. New York, Raven Press 1983; pp. 211–227.Google Scholar